Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN)

被引：0
|
作者：
Besse, Benjamin
Le Moulec, Sylvestre
Senellart, Helene
Mazieres, Julien
Barlesi, Fabrice
Dansin, Eric
Robinet, Gilles
Perol, Maurice
Moro-Sibilot, Denis
Soria, Jean-Charles
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Val de Grace Hosp, Paris, France
[3] Inst Cancerol Ouest, Nantes, France
[4] Toulouse Univ Hosp, Toulouse, France
[5] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France
[6] Ctr Oscar Lambret, F-59020 Lille, France
[7] CHU Morvan, Inst Cancerol, Brest, France
[8] Ctr Leon Berard, F-69373 Lyon, France
[9] CHU Grenoble, Thorac Oncol Unit, F-38043 Grenoble, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8059
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy
    Yoshino, Takayuki
    Oki, Eiji
    Nozawa, Hiroaki
    Eguchi-Nakajima, Takako
    Taniguchi, Hiroya
    Morita, Satoshi
    Takenaka, Naruhito
    Ozawa, Daisuke
    Shirao, Kuniaki
    ESMO OPEN, 2018, 3 (05)
  • [32] Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt plus ), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)
    Yang, J.
    Cheng, Y.
    Murakami, H.
    Yang, P-C.
    He, J.
    Nakagawa, K.
    Kang, J. H.
    Kim, J-H.
    Hozak, R.
    Nguyen, T.
    Wang, X.
    Enatsu, S.
    Puri, T.
    Orlando, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] FINAL RESULTS FROM THE IFCT-GFPC 0502 PHASE III STUDY: MAINTENANCE THERAPY IN ADVANCED NSCLC WITH EITHER GEMCITABINE (G) OR ERLOTINIB (E) VERSUS OBSERVATION (O) AFTER CISPLATIN-GEMCITABINE INDUCTION CHEMOTHERAPY (CT), WITH A PREDEFINED SECOND-LINE TREATMENT
    Perol, M.
    Zalcman, G.
    Monnet, I.
    Le Caer, H.
    Fournel, P.
    Falchero, L.
    Poudenx, M.
    Vaylet, F.
    Bizieux-Thaminy, A.
    Perol, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 124 - 125
  • [34] Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem plus pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)
    Felip, E.
    Krebs, M. G.
    Carcereny, E.
    Smeland, K. B.
    Arriola, E.
    Perez, C. Llacer
    Thompson, J.
    Paz-Ares, L.
    Gomez, M. Domine
    Olivares, J. R.
    Segarra, N. Vinolas
    Garcia-Campelo, M. R.
    Granados, A. L. O. Ortega
    Chisamore, M.
    Micklem, D.
    McCracken, N.
    Rayford, A.
    Oliva, C.
    Gorcea-Carson, C.
    Spicer, J.
    ANNALS OF ONCOLOGY, 2023, 34
  • [35] FINAL OVERALL SURVIVAL (OS) RESULTS FROM A PHASE III, RANDOMISED, OPEN-LABEL, FIRST-LINE STUDY OF GEFITINIB (G) V CARBOPLATIN/PACLITAXEL (C/P) IN CLINICALLY SELECTED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ASIA (IPASS)
    Yang, C-H.
    Fukuoka, M.
    Mok, T. S.
    Wu, Y-L.
    Thongprasert, S.
    Saijo, N.
    Chu, D-T.
    Jiang, H.
    Duffield, E. L.
    Ichinose, Y.
    ANNALS OF ONCOLOGY, 2010, 21 : 1 - 2
  • [36] Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic non-squamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial SAKK 19/05
    Zappa, F.
    Droege, C.
    Betticher, D.
    von Moos, R.
    Brutsche, M.
    Baty, F.
    Bubendorf, L.
    Ochsenbein, A.
    Leibundgut, Oppliger E.
    Gautschi, O.
    Froesch, P.
    Stahel, R.
    Rauch, D.
    Schmid, P.
    Mayer, M.
    Crowe, S.
    Brauchli, P.
    Ribi, K.
    Pless, M.
    ONKOLOGIE, 2011, 34 : 122 - 122
  • [37] Final results of a randomized phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Stinchcombe, Tom
    Raju, Robert N.
    Couch, Linda S.
    Kocs, Darren M.
    Jotte, Robert
    Wang Yunfei
    Bromund, Jane
    Marciniak, Martin D.
    Treat, Joseph
    Obasaju, Coleman K.
    Socinski, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S383 - S384
  • [38] Final results of a randomized phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Obasaju, C. K.
    Raju, R. N.
    Stinchcombe, T.
    Couch, L. S.
    Jotte, R.
    Kocs, D. M.
    Wang, Y.
    Bromund, J.
    Treat, J.
    Socinski, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with or without bevacizumab as first-line treatment in patients with advanced NSCLC: Data from EGFR wild-type cohort
    Huang, Y.
    Fang, W.
    Yang, Y.
    Zhao, Y.
    Zhao, H.
    Zhou, N.
    Zhang, Y.
    Chen, L.
    Zhou, T.
    Chen, G.
    Wu, T.
    Lu, L.
    Xue, S.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S1568 - S1569
  • [40] Updated overall survival (OS) results of randomized phase III trial of erlotiniti (E) versus (v) docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC): Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
    Ibata, Hidenori
    Ando, Masahiko
    Asami, Kazuhiro
    Okano, Yoshio
    Fukuda, Masaaki
    Nakagawa, Hideyuki
    Kozuki, Toshiyuki
    Endo, Tateo
    Tamura, Atsuhisa
    Kamimura, Mitsuhiro
    Sakamoto, Kazuhiro
    Yoshimi, Michihiro
    Soejima, Yoshifumi
    Tomizawa, Yoshio
    Isa, Shun-ichi
    Takada, Minoru
    Saka, Hideo
    Kubo, Akihito
    Kawaguchi, Tomoya
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345